Abstract
ObjectiveIn patients with a long life expectancy with high-risk (HR) prostate cancer (PCa), the chance to die from PCa is not negligible and may change significantly according to the time elapsed from surgery. The aim of this study was to evaluate long-term survival patterns in young patients treated with radical prostatectomy (RP) for HRPCa. Materials and methodsWithin a multiinstitutional cohort, 600 young patients (≤59 years) treated with RP between 1987 and 2012 for HRPCa (defined as at least one of the following adverse characteristics: prostate specific antigen>20, cT3 or higher, biopsy Gleason sum 8–10) were identified. Smoothed cumulative incidence plot was performed to assess cancer-specific mortality (CSM) and other cause mortality (OCM) rates at 10, 15, and 20 years after RP. The same analyses were performed to assess the 5-year probability of CSM and OCM in patients who survived 5, 10, and 15 years after RP. A multivariable competing risk regression model was fitted to identify predictors of CSM and OCM. ResultsThe 10-, 15- and 20-year CSM and OCM rates were 11.6% and 5.5% vs. 15.5% and 13.5% vs. 18.4% and 19.3%, respectively. The 5-year probability of CSM and OCM rates among patients who survived at 5, 10, and 15 years after RP, were 6.4% and 2.7% vs. 4.6% and 9.6% vs. 4.2% and 8.2%, respectively. Year of surgery, pathological stage and Gleason score, surgical margin status and lymph node invasion were the major determinants of CSM (all P≤0.03). Conversely, none of the covariates was significantly associated with OCM (all P≥ 0.09). ConclusionsVery long-term cancer control in young high-risk patients after RP is highly satisfactory. The probability of dying from PCa in young patients is the leading cause of death during the first 10 years of survivorship after RP. Thereafter, mortality not related to PCa became the main cause of death. Consequently, surgery should be consider among young patients with high-risk disease and strict PCa follow-up should enforce during the first 10 years of survivorship after RP.
Highlights
Bladder cancer represents one of the ten most prevalent cancers worldwide
The aggressive local surgical approach with a cystectomy is the therapy of choice
the number of eldery patients undergoing radical cystectomy will rise in the next few years
Summary
Bitte beachten Sie, dass nach Imprimatur keine weiteren Textkorrekturen, Änderungen der Autorenschaft oder der Autorenreihenfolge möglich sind. Folgende Korrekturmöglichkeiten stehen Ihnen offen: - Fügen Sie Ihre Korrekturen komfortabel mit der Kommentarfunktion Ihres PDF-Programms (z.B. Adobe Professional) direkt ins Beitrags-PDF ein. - Alternativ können Sie das PDF ausdrucken und Ihre Korrekturen gut lesbar in den Ausdruck einfügen. Hiermit gebe ich mein Manuskript direkt frei. Diese Rückantwort enthält das komplette Manuskript mit entsprechenden Korrekturwünschen. Nach ausgeführter Korrektur ist das Manuskript imprimiert. Dass größere Korrekturen oder Änderungen an der Textlänge ein späteres Publikationsdatum nach sich ziehen können
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Urologic Oncology: Seminars and Original Investigations
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
